First Keytruda Biosimilar Accepted for FDA Review, Threatening Merck's Blockbuster
MRK sits 78% above its 52-week low of $82.01.
Summary
Formycon and Zydus announced that FYB206, a biosimilar of Merck's Keytruda, has been accepted for review by the FDA. This is the first publicly announced Keytruda biosimilar to reach this stage. Keytruda is Merck's top-selling drug, generating billions in annual revenue, and biosimilar competition could erode its market share. The acceptance does not guarantee approval, but it marks a significant regulatory milestone for competitors. Merck's recent timeline shows strong Keytruda performance, including new approvals and formulations, but this development introduces a new competitive threat.
At the time of this announcement, MRK was trading at $145.66 on NYSE in the Life Sciences sector, with a market capitalization of approximately $358.9B. The 52-week trading range was $82.01 to $156.92. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.